Pharmaceutical Executive Daily reports that the FDA Vaccines and Related Biological Products Advisory Committee unanimously voted 9–0 in favor of Moderna’s investigational mRNA-1010 seasonal influenza vaccine for adults aged 50–64 and 65+. The committee confirmed that the benefit-risk profile supports
